"Our goal is helping investors grow their capital and income base from which to derive cash for their current and future needs," notes dividend expert Kelley Wright.
The editor of Investment Quality Trends explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation. Our Timely Ten list represents our current top ideas.
The Timely Ten: Blue Chip Dividends
A 'Fool-Proof' Retirement Plan for 20-Year-Olds
"I've put together a retirement blue print that will allow anyone who is 20 years old or younger to retire a multi-millionaire," says Steve Christ.
The editor of The Wealth Advisory explains, "This diversified portfolio, contains a transport, a utility, a tech company, a health care giant, and a defense contractor, all of which pay nice steady dividends with room for growth.
"All you need to start is $15,000 initial investment to go along with an additional $100 bucks a week in total contributions divided among the five stocks.
Continue reading A 'Fool-Proof' Retirement Plan for 20-Year-Olds
Abbott (ABT) and Baxter (BAX): Healthy Gains
"We follow an approach to investng that focuses on broadly diversified investments in undervalued stocks for their long-term appreciation potential," says value investor John Buckingham.
The money manager and editor of The Prudent Speculator explains, " Two recently featured ideas -- Abbott Laboratories (ABT) and Baxter International (BAX) -- are among those we feel could serve as a portfolio foundation or as a new ideas for well- diversified holdings.
Continue reading Abbott (ABT) and Baxter (BAX): Healthy Gains
The Timely 10: Best Blue Chip Dividend Buys
"High-quality stocks bought at historically low-price-to-high-yield offer the best potential for downside protection and upside appreciation," says dividend specialist Kelley Wright.The editor of IQ Trends explains, "Our 'Timely Ten' list is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years.
"Our 'Timely Ten' list is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years. Do we believe that all 10 will go up simultaneously or immediately? Of course not.
Continue reading The Timely 10: Best Blue Chip Dividend Buys
A Growth and Income Trio for All Investors
"It seems plausible to expect the index to return about 13% in the coming year; not exactly a runaway bull, but a bright enough prospect to keep us in the game," says blue chip expert Richard Band.
The editor of Profitable Investing explains, "Here are three growth-and-income names that I deem suitable for virtually all investors of any age: Abbott Laboratories (ABT), Sysco (SYY) and Time Warner (TWX).
"Whether you're three years or 33 years from retirement, now is a good time to stock up on this trio of growth and income recommendations.
Analyst Calls: ABT, ALU, CSCO, EL, F, KKR, QCOM, RIMM, SAP, STP, TIVO ...
- Qualcomm (QCOM) was upgraded to outperform from neutral at Credit Suisse.
- JPMorgan upgraded Allegheny Tech (ATI) to overweight from neutral.
- NetApp (NTAP) was upgraded to buy from hold at Canaccord.
- Estee Lauder (EL) was upgraded to perform from underperform at Oppenheimer.
- Citigroup upgraded Suntech (STP) to hold from sell.
Continue reading Analyst Calls: ABT, ALU, CSCO, EL, F, KKR, QCOM, RIMM, SAP, STP, TIVO ...
Graham/Buffett Buys: A Six-Pack of Values
"Benjamin Graham has been recognized for decades as the father of value investing; Warren Buffett is known as the Oracle of Omaha for his superior investing skills," asserts J. Royden Ward, adding, "For this report, we combine Warren Buffett's and Ben Graham's criteria for choosing stocks.
The advisor reviews Abbott Laboratories (ABT), Coach (COH), Intel (INTC), Mastercard (MA), Microsoft (MSFT) and Tupperware Brands (TUP).
Blue Chip Trio: IBM, Abbott and Automated Data
"We believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation," says dividend specialist Kelley Wright.
The editor of Investment Quality Trends explains, "Here we look at three blue chip stocks that have earned our top designation for outstanding dividend growth: IBM (IBM), Automated Data Processing (ADP) and Abbott Laboratories (ABT).
Continue reading Blue Chip Trio: IBM, Abbott and Automated Data
Analyst Calls: AAPL, ABT, AMZN, BMY, CSCO, DNB, EAT, INTU, NILE ...
- Auriga upgraded Cisco (CSCO) to buy from hold, citing the company's improving strategic position in data centers.
- Blue Nile (NILE) was raised to buy from hold by Citigroup due to the recent pullback in shares.
- DuPont Fabros (DFT) was upgraded to buy from neutral at UBS, which said that said fundamentals in the data center space have been improving.
- Baird upgraded Sterling Bancshares (SBIB) to neutral from underperform based on valuation.
- Goldman Sachs upgraded Bristol-Myers (BMY) to buy from neutral.
- Amazon.com (AMZN) was raised to conviction buy from buy by Goldman.
- Jefferies upgraded Celgene (CELG) to buy from hold.
Continue reading Analyst Calls: AAPL, ABT, AMZN, BMY, CSCO, DNB, EAT, INTU, NILE ...
Before the Bell: Futures Indicate Wall Street Could Extend Slump
It seems that Thursday's market beating into correction territory wasn't enough and Wall Street is preparing itself for yet another down day. U.S. stock futures again declined Friday, indicating markets are ready to fall even further at the open as worries over European debt, financial regulation and economic growth persist.On Thursday, Chicago Board Options Exchange Volatility (VIX) -- the so called 'fear index' -- jumped 29.6% to close at 45.79, the highest level since April 2009.
Continue reading Before the Bell: Futures Indicate Wall Street Could Extend Slump
IQ Trends' Blue Chip Buys: The 'Timely Ten'
The editor of IQ Trends explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation.
Continue reading IQ Trends' Blue Chip Buys: The 'Timely Ten'
Three Great Global Dividend Stocks
As Wall Street gyrates around in the wake of the Goldman Sachs (GS) fraud allegations, investors are starting to feel the old doubts and fears creep up again. After surging over 70% from the March 2009 lows, the market appears to be stalling at least in the short term.One place low-risk investors can take refuge is low-risk dividend stocks in reliable industries – like health care giant Abbot Laboratories (ABT) with its 3.4% yield, or in energy giant Exxon Mobil (XOM) with its 2.5% yield. Those nice payouts ensure that you'll see some returns on your investment even if things stay rocky on Wall Street. And since dividend stocks added $6.4 billion to payouts in the first quarter, the cuts we saw during the recession appear to have been reversed by many stocks.
AstraZeneca and Abbott Labs Receive FDA Response
AstraZeneca (AZN) and Abbott Laboratories (ABT) announced this morning they received a complete response letter from the Food and Drug Administration regarding their new drug application for Certriad capsules. The FDA requested more information. The companies stated that they are currently evaluating the FDA's letter and will continue discussions with the agency to see what the next step will be with the drug. AZN and ABT will then respond to the FDA's request for further information. Certriad is for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including the "bad" cholesterol (LDL), high triglycerides, and low "good" cholesterol (HDL). The active ingredients in Certirad are Crestor and Trilipix from ABT and AZN.
Continue reading AstraZeneca and Abbott Labs Receive FDA Response
Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...
- Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
- JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
- Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
- Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
- Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
- Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.
Continue reading Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...
Abbott Labs to Acquire Facet Biotech
After the closing bell Tuesday, Abbott Laboratories (ABT) announced that it will acquire Facet Biotech (FACT) for $27 per share. The transaction carries a total price tag of $722 million. Including $272 million of FACT's cash and securities, the net cost turns out to be roughly $450 million. Back in December, FACT turned down Biogen Idec's (BIIB) unsolicited takeover offer of $17.50 per share. The deal is expected to close in the second quarter, as both boards of directors have approved the deal.
Savings Experiment: Snow Removal
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
.gif)

The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal
Savings Experiment: Tissues vs. Toilet Paper
5 Signs You're Getting Robbed at the Hospital
Why Your 2012 Tax Bill May Jump By $8,000
An Insider Shares Mark Zuckerberg's 6 Secrets for Success
Which Credit Card Rewards Does the IRS Care About?
6 Strategies for Young Adults to Save More in 2012
Ford Can't Seem to Take a Joke, but It's Not the End of the World
Bank Fee Backlash Cost Big Financial Institutions More Than 2 Million Customers

